Chief Commercial Officer · X4 Pharmaceuticals, Inc (XFOR)

Mark Baldry

FY2024 is the first fiscal year CompBrief holds for Mark Baldry as a named executive officer of X4 Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,171,703

Salary $475,000Stock awards $137,703

3rd of 3 named executive officers at X4 Pharmaceuticals by FY2024 total.

3 named officers on file for X4 Pharmaceuticals, FY2024

Mark Baldry’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how X4 Pharmaceuticals’s whole pay program stands against its peers

  • X4 Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XFOR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Mark Baldry’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Baldry compensation by year

X4 Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as X4 Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$475,000
Bonus$0
Stock awards$137,703
Option awards$377,381
Non-equity incentive$167,200
Pension and deferred compensation$0
All other$14,419
Total$1,171,703

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: X4 Pharmaceuticals, Inc DEF 14A filed April 25, 2025, accession 0001628280-25-019926, and prior-year filings. Open the filing on EDGAR.

How this page was built: the X4 Pharmaceuticals, Inc filed document, accession 0001628280-25-019926. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU149,547$109,169—
Option156,292—$1.89
Option523,414—$0.92

Per the Outstanding Equity Awards at Fiscal Year-End table in X4 Pharmaceuticals, Inc's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2024 proxy (filed April 25, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-05-16Purchase—1,032$2.4825,337
2025-05-16Grant or award—1,032$2.4825,337

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

X4 Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Paula RaganPresident and Chief Executive Officer$2,145,041
Adam MostafaChief Financial Officer, Treasurer and Secretary$1,307,223
Mark Baldry · this pageChief Commercial Officer$1,171,703

The full X4 Pharmaceuticals compensation record

free company brief

This page is one person within X4 Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are X4 Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Baldry's compensation dossier · One-time report. No refunds.